Protara Therapeutics (TARA) Operating Leases (2019 - 2026)

Protara Therapeutics (TARA) has 8 years of Operating Leases data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 41.35% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 41.35% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 36.98% from the prior year.
• Operating Leases for Q1 2026 stood at $1.8 million, down from $2.1 million in the prior quarter.
• Over the last five years, Operating Leases for TARA reached as high as $6.2 million in Q1 2022 and fell as low as $1.8 million in Q1 2026.
• Historically, Operating Leases has averaged $4.4 million across 5 years, with a median of $4.5 million in 2023.
• Across the five-year window, Operating Leases soared 477.86% in 2022 and tumbled 41.35% in 2026, its largest moves.
• Year by year, Operating Leases stood at $5.5 million in 2022, then fell by 17.98% to $4.5 million in 2023, then retreated by 25.09% to $3.4 million in 2024, then plunged by 36.98% to $2.1 million in 2025, then fell by 15.3% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $1.8 million in Q1 2026, $2.1 million in Q4 2025, and $3.7 million in Q3 2025.